SRI INTERNATIONAL - NICHD: R&D: BIOLOGICAL TESTING FACILITY - DRUG PRODUCT MANUFACTURE OF ONGOING CLINICAL DEVELOPMENT: NON-SEVERABLE

On Jan 26, 2026, Department of Health and Human Services obligated $49,149.01 to SRI INTERNATIONAL for nichd: r&d: biological testing facility - drug product manufacture of ongoing clinical development: non-severable. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in MENLO PARK, CA. The contract is scheduled through Jul 31, 2026 — approximately 2 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.